Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel
Status PubMed-not-MEDLINE Language English Country Netherlands Media print-electronic
Document type Journal Article
PubMed
25877064
DOI
10.1016/j.msard.2014.03.003
PII: S2211-0348(14)00032-7
Knihovny.cz E-resources
- Keywords
- Adverse events, Dimethyl fumarate, Flushing, Gastrointestinal adverse events, Multiple sclerosis, Tolerability,
- Publication type
- Journal Article MeSH
Strategies for monitoring and managing the known adverse event (AE) profile of therapies for relapsing-remitting multiple sclerosis have become key to the optimization of patient outcomes. Delayed-release dimethyl fumarate (DMF) was associated with an increased risk of flushing and gastrointestinal (GI) AEs in clinical trials. A survey of clinicians with significant research experience using delayed-release DMF was conducted to provide guidance to clinicians using delayed-release DMF in clinical practice on the management of flushing and GI tolerability AEs. Recommendations for prophylaxis included educating the patient about flushing and GI AEs associated with delayed-release DMF and recommending administration with food. A variety of symptomatic treatments were utilized during the delayed-release DMF clinical trials in patients presenting with delayed-release DMF-related flushing or GI AEs that were severe or bothersome enough to warrant pharmacological intervention.
Baylor Institute for Immunology Research 3434 Live Oak Street Dallas TX 75204 USA
Charles University Prague Katerinska 30 12808 Praha 2 Prague Czech Republic
Mellen Center for Multiple Sclerosis Cleveland Clinic 9500 Euclid Avenue U10 Cleveland OH 44195 USA
Ruhr University Bochum Gudrunstr 56 44791 Bochum Germany
St Vincent׳s University Hospital and University College Dublin Elm Park Dublin 4 Ireland
References provided by Crossref.org
